SELB SELECTA BIOSCIENCES

Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy

Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy
EN
08/10/2020

Underlying

SELBSELECTA BIOSCIENCES

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SELECTA BIOSCIENCES

 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Reports Third Quarter 2025 Financial Results an...

Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected by end of year Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected by end of year Approximately $145.1 million cash, cash equivalents and restricted cash as of September 30, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phas...

November 6, 2025 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On October 27, 2025, the Company issued to one employee an option to purchase an aggregate of 50,000 shares of the Company’s common stock with an exercise price of $8.85, the closing trading price of the Company’s common stock on the Nasdaq Global Market on ...

October 30, 2025 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairm...

Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that Carsten Brunn, Ph.D., was named as Chairman of the Board of Directors, effective October 29, 2025. Dr. Brunn, who currently serves as the Company’s President and Chief Executive Officer and as a member of the Board, will succeed Carrie S. Cox, who is stepping down t...

October 30, 2025 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Announces New Employment Inducement Grant FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On October 2, 2025, the Company issued to this employee an option to purchase an aggregate of 9,700 shares of the Company’s common stock with an exercise price of $10.34, the closing trading price of the Company’s common stock on the Nasdaq Global Market on ...

October 3, 2025 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics to Participate in Upcoming Investor Conferences FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September: A fireside chat at the Cantor Global Healthcare Conference 2025 at 11:30 a.m. ET on Thursday, September 4, 2025A fireside chat at Morgan Stanley’s 23rd Annual Healthcare Conference at 4:05 p.m. ET on Tuesday, Sept...

August 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch